Worldwide over 1 million women diagnosed with breast cancer undergo BCT (surgery with follow-up radiotherapy) annually as an alternative to mastectomy, whereby both procedures result in comparable survival rate for early breast cancer.
Number of peer-reviewed scientific papers
Number of projects completed
Number of patents and patent pending
Number of conferences
Valérie has 14-yr experience in technology R&D, design and commercialization. She is co-inventor of NexPlasmaGen’s technology.
Audrey has 5-yr experience in conducting preclinical trials for breast and other cancers. She works at NexPlasmaGen and at the CR-CHUM.
Philip is an Assistant Professor at the Department of Radiation Oncology, University of Toronto. He is a clinician-investigator at the CR-CHUM. He leads NexPlasmaGen’s clinical program and is co-inventor of NexPlasmaGen’s technology.
Julie has 7-yr experience supervising Dr. Wong’s laboratory and plays a crucial role in NexPlasmaGen preclinical trials. She works at the CR-CHUM.
Valérie is currently the sole board member of NexPlasmaGen. New members will be added as we grow the company.
MDCM, MSc, FRPC